129 related articles for article (PubMed ID: 33097773)
1. Author Correction: Evaluation of Radiation dosimetry of
Zhang J; Zhang J; Xu X; Lu L; Hu S; Liu C; Cheng J; Song S; Zhang Y; Shi LQ
Sci Rep; 2020 Oct; 10(1):18494. PubMed ID: 33097773
[TBL] [Abstract][Full Text] [Related]
2.
Santos-Cuevas C; Davanzo J; Ferro-Flores G; García-Pérez FO; Ocampo-García B; Ignacio-Alvarez E; Gómez-Argumosa E; Pedraza-López M
Nucl Med Biol; 2017 Sep; 52():1-6. PubMed ID: 28575794
[TBL] [Abstract][Full Text] [Related]
3. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
4.
Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
6. Head to head comparison performance of
García-Pérez FO; Davanzo J; López-Buenrostro S; Santos-Cuevas C; Ferro-Flores G; Jímenez-Ríos MA; Scavuzzo A; Santana-Ríos Z; Medina-Ornelas S
Am J Nucl Med Mol Imaging; 2018; 8(5):332-340. PubMed ID: 30510850
[TBL] [Abstract][Full Text] [Related]
7. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
11. PSMA SPECT/CT with
Schmidkonz C; Goetz TI; Kuwert T; Ritt P; Prante O; Bäuerle T; Goebell P; Cordes M
Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
[TBL] [Abstract][Full Text] [Related]
12. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Author Correction: Evaluation of T1 relaxation time in prostate cancer and benign prostate tissue using a Modified Look-Locker inversion recovery sequence.
Baur ADJ; Hansen CM; Rogasch J; Posch H; Elezkurtaj S; Maxeiner A; Erb-Eigner K; Makowski MR
Sci Rep; 2020 Mar; 10(1):5249. PubMed ID: 32184409
[TBL] [Abstract][Full Text] [Related]
15. Comparison of hybrid
Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
17. Patient-specific dosimetry of
Hou X; Birkenfeld B; Piwowarska-Bilska H; Celler A
EJNMMI Phys; 2017 Oct; 4(1):24. PubMed ID: 29030760
[TBL] [Abstract][Full Text] [Related]
18. Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells.
Takahashi H; Yumoto K; Yasuhara K; Nadres ET; Kikuchi Y; Buttitta L; Taichman RS; Kuroda K
Sci Rep; 2019 Nov; 9(1):17455. PubMed ID: 31767898
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: The evolutionary history of lethal metastatic prostate cancer.
Gundem G; Van Loo P; Kremeyer B; Alexandrov LB; Tubio JMC; Papaemmanuil E; Brewer DS; Kallio HML; Hägnäs G; Annala M; Kivinummi K; Goody V; Latimer C; O'Meara S; Dawson KJ; Isaacs W; Emmert-Buck MR; Nykter M; Foster C; Kote-Jarai Z; Easton D; Whitaker HC; ; Neal DE; Cooper CS; Eeles RA; Visakorpi T; Campbell PJ; McDermott U; Wedge DC; Bova GS
Nature; 2020 Aug; 584(7820):E18. PubMed ID: 32728210
[TBL] [Abstract][Full Text] [Related]
20. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
